Envision Healthcare Holdings Inc

Most Recent

  • uploads///AdobeStock_

    Tesla Bear Jim Chanos Shorting Grubhub, DaVita

    On September 19, at Delivering Alpha Conference, Jim Chanos said Grubhub (GRUB) is a very good short. He said that Guruhub is almost not making any money.

    By Rabindra Samanta
  • uploads///Jim Chanos Shorting Bets
    Fund Managers

    Will Jim Chanos’s Short Bet on Mednax and Envision Be Profitable?

    Mednax and Envision Healthcare’s (EVHC) stock price fell 1.45% and 1.72%, respectively, on Wednesday, July 18.

    By Sarah Sands
  • uploads///Chart
    Company & Industry Overviews

    Envision Healthcare to Be Acquired by KKR

    On June 11, Envision entered into a definitive acquisition agreement with KKR.

    By Mike Benson
  • uploads///people _

    Why Envision Healthcare Stock Rose ~2.4% Last Week

    Healthcare service provider Envision Healthcare (EVHC) announced its agreement to be acquired by KKR (KKR) last week.

    By Mike Benson
  • uploads///feit
    Company & Industry Overviews

    KKR to Acquire Envision Healthcare

    On June 11, KKR entered into an agreement with Envision Healthcare. KKR will acquire Envision Healthcare in an all-cash transaction.

    By Daniel Collins
  • uploads///Gainers
    Company & Industry Overviews

    Mattel: S&P 500’s Top Gainer on April 11

    Mattel, which is an American multinational toy manufacturing company, was the S&P 500’s top gainer on Wednesday.

    By Val Kensington
    Company & Industry Overviews

    UnitedHealth Group Drops Out of the Bid to Acquire Envision

    On March 14, 2018, it was reported that UnitedHealth Group is no longer interested in acquiring Envision Healthcare

    By Sarah Collins
  • uploads///crutches _
    Company & Industry Overviews

    What Analysts Recommend for Universal Health Services

    Of the 18 analysts covering Universal Health Services in February 2018, five analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating.

    By Kenneth Smith
  • uploads///doctors _
    Company & Industry Overviews

    Analysts’ Ratings for Genesis Healthcare and Peers in February

    Of the five analysts covering Genesis Healthcare in February 2018, one has given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///Gainers
    Company & Industry Overviews

    Envision Healthcare Was the S&P 500’s Top Gainer on December 27

    Envision Healthcare (EVHC), an American healthcare company and national hospital-based physician group, was the top gainer of the S&P 500 on December 27.

    By Val Kensington
  • uploads///Mednax Risks
    Company & Industry Overviews

    Key Risks Facing Mednax in 2017

    Mednax (MD) bills payors for services provided to patients. These payors consist of government programs like Medicare and Medicaid, contracted managed care, third parties, and private pay patients.

    By Kenneth Smith
  • uploads///mednax revenue growth
    Company & Industry Overviews

    Understanding Mednax’s Financial Position

    In 3Q17, hurricanes negatively affected Mednax’s (MD) revenues by close to $2 million. According to the company, acquisitions in radiology, anesthesia, and neonatology contributed around 430 basis points to revenue growth.

    By Kenneth Smith
  • uploads///Mednax Business Strategy
    Company & Industry Overviews

    A Closer Look at Mednax’s Business Strategy

    Mednax (MD) has a proven track record of expertise in the administration of physician services and a methodical approach to clinical data warehousing in fields such as research, education, and quality.

    By Kenneth Smith
  • uploads///Mednax Analysts Reco
    Company & Industry Overviews

    The Latest Wall Street Recommendations for Mednax

    Of the total 14 analysts covering Mednax (MD) in December 2017, three analysts have given the stock a “buy” or higher rating and ten have given it a “hold” rating while one analyst has given it a “sell” rating.

    By Kenneth Smith
  • uploads///EVHC AMSG transformative combination

    The Amsurg-Envision Material Adverse Effect Clause: Part 2

    In this part of the series, we’ll look at the MAE clause of the Amsurg (AMSG) merger agreement with Envision Healthcare (EVHC) and how Amsurg could back out of the deal.

    By Brent Nyitray, CFA, MBA
  • uploads///EVHC AMSG best in class

    What’s the Main Regulatory Risk of the Envision-Amsurg Deal?

    In the risk arbitrage world, a 2.8% annualized return is pretty small. There’s some overlap that could concern regulators. The main risk would be the timing risk.

    By Brent Nyitray, CFA, MBA
  • uploads///EVHC AMSG combination

    Can the Amsurg-Envision Transaction Get Antitrust Approval?

    In the case of Amsurg (AMSG) and Envision (EVHC), the gating item will depend on how closely antitrust regulators look at the transaction.

    By Brent Nyitray, CFA, MBA
  • uploads///EVHC AMSG summary terms

    What’s the Rationale for the Amsurg-Envision Merger?

    Amsurg and Envision are merging. Envision shareholders will receive 0.334 shares of Amsurg stock for each share of Envision they hold.

    By Brent Nyitray, CFA, MBA
  • uploads///EVHC AMSG spread

    Amsurg and Envision Merge to Form a Healthcare Services Juggernaut

    On June 15, Amsurg (AMSG) and Envision (EVHC) announced a merger. Envision will hold 53% of the new company and Amsurg will hold 47%.

    By Brent Nyitray, CFA, MBA
  • uploads///md pm
    Earnings Report

    MEDNAX Revenue and Income Rose After 3Q15 Results

    MEDNAX’s YTD price movement was a mix of rises and falls in 2015. After the earnings report, MEDNAX fell 3.4% to close at $71.3 per share as of October 29, 2015.

    By Gabriel Kane
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.